# Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

> **NCT04433572** · PHASE3 · RECRUITING · sponsor: **Mercator MedSystems, Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Peripheral Artery Disease
- Critical Limb Ischemia

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Saline placebo

## Key facts

- **NCT ID:** NCT04433572
- **Lead sponsor:** Mercator MedSystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2028-02-01
- **Final completion:** 2032-08-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433572, "Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04433572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*